Cancer-testis antigen GAGE-1 expression and serum immunoreactivity in hepatocellular carcinoma.

AIM: To explore the use of cancer-testis antigen G antigen 1 (GAGE-1) in the diagnosis and potential therapeutic targeting of hepatocellular carcinoma (HCC), we measured the expression of GAGE-1 protein levels in HCC tissues and its serum immunoreactivity in HCC patients. MATERIALS AND METHODS: We detected the expression of GAGE-1 protein in HCC by immunohistochemistry (IHC). We then analyzed the clinical significance of GAGE-1 expression in HCC with respect to clinicopathological parameters. We observed positive anti-GAGE-1 antibody reactivity in HCC patient serum, liver cirrhosis patients (LC), hepatitis B patients (HB), and normal human individuals (NHS) by enzyme-linked immunosorbent assay. RESULTS: The IHC results showed that the positive rates of GAGE-1 protein expression in cancer tissues and adjacent tissues were 43.3% (26/60) and 5% (3/60), respectively. The expression level of GAGE-1 protein in HCC tissues was significantly higher than that in tumor-adjacent tissues (P < 0.05). Positive GAGE-1 protein expression was not correlated with clinicopathological parameters (P > 0.05). Positive serum anti-GAGE-1 antibody reactivity in HCC patients, LC, HB, and NHS was 23.33% (14/59), 13.1% (8/61), 3.3% (2/60), and 3.4% (2/59), respectively. The frequency of anti-GAGE-1 antibody-positive sera in HCC patients and LC was significantly different than that in HB and NHS (P < 0.01), but no significant differences were found between HCC patients and LC (P = 0.485) or between HB and NHS (P = 0.410). Positive anti-GAGE-1 antibody reactivity was not correlated with clinicopathological parameters (P > 0.05). CONCLUSION: These data illustrate that the GAGE-1 protein exhibits moderate cancer-restricted pattern of expression and immunogenicity, laying the foundation for the application of GAGE-1 in immunotherapy and for the diagnosis of HCC.

Nucleophilic addition to the ethynyl group in ethynylestradiol catalyzed by crown ether-copper (1) iodide.

A new and convenient synthetic route to acetylation of estrogens is described. Benzo-15-crown-5 and cuprous iodide-mixed catalyst catalyzed the nucleophilic addition of 2,4-dibromoethynylestradiol, resulting in the formation of a new compound, 2,4-dibromo-17 alpha-acetylestradiol, of which the structure was characterized by infrared, UV, 1H nuclear magnetic resonance, mass spectra, and elemental analysis. It was found that the yield of this approach is much higher than that obtained in the hydration of usual acetylenic compounds.

A new synthetic route to 2- and 4-methoxyestradiols by nucleophilic substitution.

A new snythetic route to 2- and 4-methoxyestradiols is described. Benzo-15-crown-5 with CuI catalyzes the specific nucleophilic substitution at the carbon atom carrying a non-activated halogen on ring A of the estradiol.